Physician profile
Wendell E Petty
NPI 1457312308
$11,626.69
in general payments reported to CMS, 2019-2025
36 companies · $2,467 in 2025
The $2,467 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $760 · 2021: $1,550 · 2022: $1,482 · 2023: $2,343 · 2024: $2,267 · 2025: $2,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,022 · Education: $54.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,021.60 |
| Education | $54.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,402.69 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,698.83 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,213.15 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $1,206.40 | 2019-2025 | Prolastin-C Liquid, Gamunex-C, Xembify |
| Csl Behring | $1,047.40 | 2020-2025 | Hizentra, Haegarda |
| Genzyme Corporation | $656.04 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $429.88 | 2021-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $410.99 | 2020-2025 | Eohilia, Takhzyro, Cuvitru |
| Novartis Pharmaceuticals Corporation | $298.30 | 2019-2025 | |
| Blueprint Medicines Corporation | $267.59 | 2023-2025 | Ayvakit |
| Mylan Specialty L.P. | $245.09 | 2019-2024 | Yupelri |
| Pharming Healthcare, INC. | $222.00 | 2019-2025 | Ruconest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.04 | 2019-2023 | Spiriva Respimat |
| Horizon Therapeutics Plc | $145.13 | 2019-2023 | Actimmune |
| Pfizer INC. | $140.60 | 2020-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $105.00 | 2021-2023 | Airduo Digihaler |
| Aimmune Therapeutics, INC. | $99.36 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $96.52 | 2019-2020 | |
| Amgen INC. | $87.35 | 2022-2025 | Actimmune, Tezspire |
| Ionis Pharmaceuticals, INC. | $86.77 | 2025 | Dawnzera |
| Sanofi US Services INC. | $66.86 | 2025 | |
| Octapharma USA, INC. | $61.58 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $58.27 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $54.95 | 2024 | |
| Biocryst Pharmaceuticals, INC. | $52.81 | 2020 | |
| Greer Laboratories, INC. | $47.21 | 2024 | Palforzia |
| Uswm, LLC | $40.40 | 2021 | |
| Optinose US, INC. | $36.31 | 2022-2023 | |
| X4 Pharmaceuticals, INC. | $29.93 | 2024 | Xolremdi |
| Cycle Pharmaceuticals INC | $28.31 | 2024 | Sajazir |
| Circassia INC. | $27.97 | 2019-2020 | |
| Baxter Healthcare | $27.22 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Verona Pharma, INC. | $26.26 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $17.68 | 2021 | |
| Kaleo, INC. | $17.41 | 2023 | Auvi-Q |
| Genentech USA, INC. | $16.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendell Petty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.